| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2083078 | Drug Discovery Today: Therapeutic Strategies | 2006 | 6 Pages |
Abstract
The majority of drugs currently prescribed for the treatment of depression inhibit the reuptake of serotonin and/or norepinephrine. The strategy for developing triple reuptake inhibitors (TRIs) is based on preclinical and clinical studies indicating that adding a dopaminergic component to a single or dual uptake inhibitor will improve these therapies in one or more dimensions.
Section editors:David Sibley – National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, USAC. Anthony Altar – Psychiatric Genomics, Gaithersburg, USATheresa Branchek – Lundbeck Research, Paramus, USA
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biotechnology
Authors
Phil Skolnick, Anthony S. Basile,